(CNN Español) – The President of the Council of Ministers of Peru Violeta Bermúdez rejects the report on the vaccine of Sinopharm that the local television company Willax reported this year, which said that the results of the clinical trial in Peru had an increase of 33% in the case of the Wuhan ca and 11.5% with the Beijing cepa.
“This governing body of transition and emergence is a transparent governing body, we will not use the public or manipulate the information. Usted dobbeltstene que tengo que dem demonstrat eficacia de una vacuna. When Peru signed a contract to acquire one million Sinopharm vacancies based on technical, clinical information provided by Digemid in respect of the clinical trials conducted in the United Arab Emirates and its 79 vacancies , 3%. There are no content with it, there are publications, international studies, the experts say, not the word yo, about the efficiency of the vacancy that we have purchased in Peru. If so, please do not inform the public, ”said Bermúdez.
The President of the Council of Ministers recorded that the country acquired this vacancy on the 6th of January. Peru has contracted companies in the field of firefighting and has requested vacancies with other laboratories such as Pfizer (20 million) and AstraZeneca (14 million). With respect to the Sinopharm vaccine, of which Peru comprises 38 million doses, Bermúdez also signaled that this vaccine “is applied in many places around the world, of which it is one of the most widely used vaccines in the world fecha ”.
Bermúdez finalized declaring that “this governing body of transition and emergence will defend public health and democracy without the constant attacks that come receiving, these attacks have as an object to disrupt the inoculation and polarize the population 5 a.
The Sinophar company issued a communication in support of the Chinese Embassy in Peru, stating that “The adjudication of the COVID-19 cases is currently being agreed upon and the requirements of the Protocol have not been established. definitive dates of the clinical trial in Peru. The data in the report are incomplete, do not contain a scientific character, and do not reflect an authentic manner or complete or effective protection of the window. No tiene valor de referencia. With respect to our false reporters our company reserves the right to demand responsibility ».
Carolith García, principal investigator of clinical trials that led the University of Cayetano Heredia with the Chinese laboratory Sinopharm in Peru told RPP News that “the information that is being published in another medium is a preliminary report of the project results” and that the results of the dosing efficiency dosing will be known in one 8 weeks.
García agrees that this information also includes information that will not be broadcast on Willax TV. “The level of efficacy for patients who have a positive PCR and are hospitalized is 91%, meaning that a person who has been vaccinated with the Beijing vaccine has 91% less chance of being hospitalized than a person who has received a placebo” .